Stem definition | Drug id | CAS RN |
---|---|---|
anxiolytics, buspirone derivatives | 437 | 36505-84-7 |
Dose | Unit | Route |
---|---|---|
30 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.02 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.10 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 2.59 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 3.90 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 29, 1986 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Completed suicide | 465.18 | 12.61 | 449 | 21573 | 145471 | 46518569 |
Anxiety | 136.58 | 12.61 | 279 | 21743 | 181678 | 46482362 |
Depression | 129.03 | 12.61 | 262 | 21760 | 169842 | 46494198 |
Serotonin syndrome | 107.33 | 12.61 | 90 | 21932 | 24130 | 46639910 |
Suicidal ideation | 99.95 | 12.61 | 128 | 21894 | 56254 | 46607786 |
Toxicity to various agents | 86.32 | 12.61 | 257 | 21765 | 211509 | 46452531 |
Withdrawal syndrome | 61.63 | 12.61 | 58 | 21964 | 18076 | 46645964 |
Neuroleptic malignant syndrome | 48.57 | 12.61 | 41 | 21981 | 11081 | 46652959 |
Overdose | 44.54 | 12.61 | 127 | 21895 | 101852 | 46562188 |
Stiff person syndrome | 42.29 | 12.61 | 11 | 22011 | 174 | 46663866 |
Panic attack | 39.09 | 12.61 | 48 | 21974 | 20194 | 46643846 |
Agitation | 37.96 | 12.61 | 82 | 21940 | 55333 | 46608707 |
Rheumatoid arthritis | 37.33 | 12.61 | 35 | 21987 | 240180 | 46423860 |
Tremor | 35.85 | 12.61 | 128 | 21894 | 115511 | 46548529 |
Poisoning | 35.14 | 12.61 | 38 | 21984 | 13956 | 46650084 |
Drug withdrawal syndrome | 33.37 | 12.61 | 52 | 21970 | 27332 | 46636708 |
Cardio-respiratory arrest | 32.65 | 12.61 | 81 | 21941 | 59788 | 46604252 |
Insomnia | 31.18 | 12.61 | 157 | 21865 | 164767 | 46499273 |
Febrile neutropenia | 31.02 | 12.61 | 4 | 22018 | 94623 | 46569417 |
Disturbance in attention | 30.50 | 12.61 | 54 | 21968 | 31506 | 46632534 |
Weight increased | 29.99 | 12.61 | 155 | 21867 | 164318 | 46499722 |
Anoxia | 29.48 | 12.61 | 9 | 22013 | 260 | 46663780 |
Extrapyramidal disorder | 29.00 | 12.61 | 31 | 21991 | 11237 | 46652803 |
Neutropenia | 27.15 | 12.61 | 17 | 22005 | 143187 | 46520853 |
Mydriasis | 27.10 | 12.61 | 29 | 21993 | 10524 | 46653516 |
Hypothermia | 27.01 | 12.61 | 31 | 21991 | 12152 | 46651888 |
Plasma cell mastitis | 26.90 | 12.61 | 5 | 22017 | 13 | 46664027 |
Respiratory arrest | 26.62 | 12.61 | 53 | 21969 | 33763 | 46630277 |
Intentional overdose | 25.58 | 12.61 | 78 | 21944 | 64866 | 46599174 |
Drug screen false positive | 25.50 | 12.61 | 11 | 22011 | 866 | 46663174 |
Somnolence | 24.16 | 12.61 | 141 | 21881 | 156380 | 46507660 |
Treatment failure | 24.09 | 12.61 | 7 | 22015 | 93080 | 46570960 |
Thrombocytopenia | 24.03 | 12.61 | 15 | 22007 | 126566 | 46537474 |
Migraine | 23.85 | 12.61 | 80 | 21942 | 69946 | 46594094 |
Suicide attempt | 23.48 | 12.61 | 68 | 21954 | 54968 | 46609072 |
Emotional disorder | 23.43 | 12.61 | 29 | 21993 | 12295 | 46651745 |
Anaemia | 23.34 | 12.61 | 54 | 21968 | 255725 | 46408315 |
Injection site mass | 23.31 | 12.61 | 32 | 21990 | 15008 | 46649032 |
False positive investigation result | 23.09 | 12.61 | 9 | 22013 | 547 | 46663493 |
Pre-existing condition improved | 22.17 | 12.61 | 21 | 22001 | 6591 | 46657449 |
Panic disorder | 21.51 | 12.61 | 14 | 22008 | 2547 | 46661493 |
Product dose omission issue | 21.15 | 12.61 | 144 | 21878 | 168376 | 46495664 |
Pancytopenia | 20.93 | 12.61 | 7 | 22015 | 85051 | 46578989 |
Suspected suicide | 19.98 | 12.61 | 17 | 22005 | 4644 | 46659396 |
Fibromyalgia | 19.52 | 12.61 | 49 | 21973 | 36414 | 46627626 |
Sleep apnoea syndrome | 18.94 | 12.61 | 36 | 21986 | 22165 | 46641875 |
Anticholinergic syndrome | 17.99 | 12.61 | 11 | 22011 | 1795 | 46662245 |
Exposure via ingestion | 17.70 | 12.61 | 14 | 22008 | 3453 | 46660587 |
Bipolar disorder | 17.17 | 12.61 | 19 | 22003 | 7158 | 46656882 |
Rhabdomyolysis | 17.13 | 12.61 | 51 | 21971 | 41858 | 46622182 |
Surgery | 16.81 | 12.61 | 40 | 21982 | 28745 | 46635295 |
Mania | 16.70 | 12.61 | 23 | 21999 | 10823 | 46653217 |
Exposure during pregnancy | 16.51 | 12.61 | 16 | 22006 | 108196 | 46555844 |
Memory impairment | 16.30 | 12.61 | 76 | 21946 | 77261 | 46586779 |
Generalised anxiety disorder | 16.26 | 12.61 | 10 | 22012 | 1650 | 46662390 |
Bradykinesia | 16.05 | 12.61 | 14 | 22008 | 3952 | 46660088 |
Drug intolerance | 16.00 | 12.61 | 28 | 21994 | 147021 | 46517019 |
Flat affect | 15.80 | 12.61 | 9 | 22013 | 1289 | 46662751 |
Irritability | 15.60 | 12.61 | 39 | 21983 | 28907 | 46635133 |
Infusion related reaction | 15.40 | 12.61 | 15 | 22007 | 101193 | 46562847 |
Hallucination, auditory | 15.35 | 12.61 | 22 | 22000 | 10734 | 46653306 |
Cerebellar infarction | 15.25 | 12.61 | 10 | 22012 | 1842 | 46662198 |
Muscle rigidity | 15.15 | 12.61 | 21 | 22001 | 9940 | 46654100 |
Anger | 15.13 | 12.61 | 23 | 21999 | 11829 | 46652211 |
Autonomic nervous system imbalance | 15.04 | 12.61 | 11 | 22011 | 2415 | 46661625 |
Behaviour disorder | 14.73 | 12.61 | 10 | 22012 | 1951 | 46662089 |
Sedation | 14.66 | 12.61 | 33 | 21989 | 22877 | 46641163 |
Diabetic neuropathy | 14.59 | 12.61 | 13 | 22009 | 3776 | 46660264 |
General physical health deterioration | 14.55 | 12.61 | 20 | 22002 | 115749 | 46548291 |
Therapy cessation | 14.48 | 12.61 | 36 | 21986 | 26593 | 46637447 |
Akathisia | 14.42 | 12.61 | 18 | 22004 | 7696 | 46656344 |
Nightmare | 14.26 | 12.61 | 27 | 21995 | 16571 | 46647469 |
Depressed mood | 14.04 | 12.61 | 41 | 21981 | 33278 | 46630762 |
Narcolepsy | 14.01 | 12.61 | 8 | 22014 | 1151 | 46662889 |
Mental disorder | 14.01 | 12.61 | 32 | 21990 | 22393 | 46641647 |
Renal impairment | 13.85 | 12.61 | 9 | 22013 | 74363 | 46589677 |
Alcoholism | 13.62 | 12.61 | 10 | 22012 | 2208 | 46661832 |
Product substitution issue | 13.60 | 12.61 | 25 | 21997 | 15006 | 46649034 |
Alcohol withdrawal syndrome | 13.52 | 12.61 | 7 | 22015 | 830 | 46663210 |
Hyperhidrosis | 13.47 | 12.61 | 80 | 21942 | 89228 | 46574812 |
Cognitive disorder | 13.32 | 12.61 | 43 | 21979 | 36840 | 46627200 |
Delusion | 13.29 | 12.61 | 21 | 22001 | 11167 | 46652873 |
Illness | 13.23 | 12.61 | 22 | 22000 | 12202 | 46651838 |
Macroglossia | 13.11 | 12.61 | 6 | 22016 | 544 | 46663496 |
Accidental death | 12.94 | 12.61 | 9 | 22013 | 1826 | 46662214 |
Cardiac death | 12.77 | 12.61 | 6 | 22016 | 577 | 46663463 |
Lower respiratory tract infection | 12.76 | 12.61 | 5 | 22017 | 55084 | 46608956 |
Psychotic disorder | 12.74 | 12.61 | 31 | 21991 | 22590 | 46641450 |
Appetite disorder | 12.72 | 12.61 | 14 | 22008 | 5240 | 46658800 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Completed suicide | 129.65 | 15.98 | 147 | 8005 | 99345 | 29844981 |
Anxiety | 115.70 | 15.98 | 132 | 8020 | 89739 | 29854587 |
Serotonin syndrome | 85.81 | 15.98 | 56 | 8096 | 17835 | 29926491 |
Suicidal ideation | 71.63 | 15.98 | 67 | 8085 | 36047 | 29908279 |
Agitation | 55.64 | 15.98 | 71 | 8081 | 54002 | 29890324 |
Electrocardiogram QRS complex prolonged | 40.93 | 15.98 | 21 | 8131 | 4256 | 29940070 |
Depression | 37.92 | 15.98 | 79 | 8073 | 90358 | 29853968 |
Sedation | 37.58 | 15.98 | 33 | 8119 | 16340 | 29927986 |
Insomnia | 35.08 | 15.98 | 78 | 8074 | 93258 | 29851068 |
Tremor | 34.15 | 15.98 | 68 | 8084 | 75295 | 29869031 |
Irritability | 33.23 | 15.98 | 36 | 8116 | 23014 | 29921312 |
Muscle necrosis | 32.59 | 15.98 | 11 | 8141 | 773 | 29943553 |
Lens dislocation | 28.65 | 15.98 | 5 | 8147 | 17 | 29944309 |
Withdrawal syndrome | 28.51 | 15.98 | 24 | 8128 | 11226 | 29933100 |
Akathisia | 27.11 | 15.98 | 18 | 8134 | 5886 | 29938440 |
Toxicity to various agents | 26.72 | 15.98 | 107 | 8045 | 177076 | 29767250 |
Anger | 26.70 | 15.98 | 23 | 8129 | 11097 | 29933229 |
Neuroleptic malignant syndrome | 26.24 | 15.98 | 27 | 8125 | 16268 | 29928058 |
Product dose omission issue | 25.26 | 15.98 | 68 | 8084 | 91563 | 29852763 |
Nightmare | 25.06 | 15.98 | 23 | 8129 | 12053 | 29932273 |
Hypertensive urgency | 23.40 | 15.98 | 5 | 8147 | 58 | 29944268 |
Fear of weight gain | 22.61 | 15.98 | 4 | 8148 | 15 | 29944311 |
Feeling abnormal | 19.70 | 15.98 | 46 | 8106 | 56710 | 29887616 |
Electrocardiogram QT prolonged | 19.51 | 15.98 | 35 | 8117 | 35800 | 29908526 |
Seizure | 19.48 | 15.98 | 65 | 8087 | 98410 | 29845916 |
Orthostatic tremor | 18.33 | 15.98 | 3 | 8149 | 6 | 29944320 |
Atrioventricular block second degree | 17.97 | 15.98 | 11 | 8141 | 3129 | 29941197 |
Gynaecomastia | 17.51 | 15.98 | 16 | 8136 | 8335 | 29935991 |
Pneumonia | 17.46 | 15.98 | 41 | 8111 | 334265 | 29610061 |
Drug withdrawal syndrome | 17.25 | 15.98 | 24 | 8128 | 19785 | 29924541 |
Panic attack | 16.98 | 15.98 | 16 | 8136 | 8665 | 29935661 |
Feeling of despair | 16.42 | 15.98 | 7 | 8145 | 933 | 29943393 |
Dysphoria | 16.20 | 15.98 | 9 | 8143 | 2139 | 29942187 |
Bipolar disorder | 16.11 | 15.98 | 11 | 8141 | 3765 | 29940561 |
Source | Code | Description |
---|---|---|
ATC | N05BE01 | NERVOUS SYSTEM PSYCHOLEPTICS ANXIOLYTICS Azaspirodecanedione derivatives |
CHEBI has role | CHEBI:35474 | minor tranquilisers |
CHEBI has role | CHEBI:35717 | sedatives |
CHEBI has role | CHEBI:35941 | serotonergic agonists |
CHEBI has role | CHEBI:76779 | prolyl oligopeptidase (ec 3.4.21.26) inhibitor |
MeSH PA | D014151 | Anti-Anxiety Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D011619 | Psychotropic Drugs |
MeSH PA | D018490 | Serotonin Agents |
MeSH PA | D017366 | Serotonin Receptor Agonists |
MeSH PA | D014149 | Tranquilizing Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Generalized anxiety disorder | indication | 21897009 | DOID:14320 |
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.51 | Basic |
pKa2 | 2.23 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
5-hydroxytryptamine receptor 1A | GPCR | PARTIAL AGONIST | EC50 | 7.25 | WOMBAT-PK | CHEMBL | |||
D(4) dopamine receptor | GPCR | Ki | 7 | WOMBAT-PK | |||||
Alpha-1D adrenergic receptor | GPCR | Ki | 6.28 | DRUG MATRIX | |||||
D(2) dopamine receptor | GPCR | Ki | 7.68 | WOMBAT-PK | |||||
Alpha-1A adrenergic receptor | GPCR | Ki | 6.44 | WOMBAT-PK | |||||
5-hydroxytryptamine receptor 2C | GPCR | Ki | 6.04 | WOMBAT-PK | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 6.41 | WOMBAT-PK | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 6.60 | WOMBAT-PK | |||||
Cytochrome P450 3A4 | Enzyme | Ki | 5.13 | WOMBAT-PK | |||||
Solute carrier family 22 member 2 | Transporter | IC50 | 4.92 | CHEMBL | |||||
D(3) dopamine receptor | GPCR | Ki | 6.18 | CHEMBL | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.40 | CHEMBL | |||||
Multidrug and toxin extrusion protein 2 | Transporter | IC50 | 4.34 | CHEMBL | |||||
Multidrug and toxin extrusion protein 1 | Transporter | IC50 | 5.77 | CHEMBL | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 7.32 | WOMBAT-PK | |||||
Membrane-associated progesterone receptor component 1 | Membrane receptor | IC50 | 5.47 | DRUG MATRIX | |||||
D(1A) dopamine receptor | GPCR | Ki | 5.21 | CHEMBL | |||||
Adrenergic receptor alpha-1 | GPCR | Ki | 6.86 | CHEMBL | |||||
D(2) dopamine receptor | GPCR | Ki | 7.36 | CHEMBL | |||||
Serotonin 2 (5-HT2) receptor | GPCR | Ki | 6.76 | CHEMBL | |||||
Dopamine receptor | GPCR | IC50 | 6.92 | CHEMBL | |||||
Adrenergic receptor alpha-2 | GPCR | IC50 | 5 | CHEMBL | |||||
Alpha-1A adrenergic receptor | GPCR | IC50 | 4.80 | CHEMBL | |||||
Alpha-2A adrenergic receptor | GPCR | IC50 | 5 | CHEMBL | |||||
Serotonin 1 (5-HT1) receptor | GPCR | IC50 | 7.02 | CHEMBL | |||||
5-hydroxytryptamine receptor 1B | GPCR | Ki | 7.77 | CHEMBL | |||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 8.42 | CHEMBL | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 7.32 | CHEMBL | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 6.75 | CHEMBL | |||||
D(2) dopamine receptor | GPCR | Ki | 6.92 | CHEMBL | |||||
5-hydroxytryptamine receptor 2C | GPCR | IC50 | 6 | CHEMBL | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 6.32 | CHEMBL | |||||
5-hydroxytryptamine receptor 7 | GPCR | ANTAGONIST | Ki | 6.40 | IUPHAR | ||||
5-hydroxytryptamine receptor 7 | GPCR | AGONIST | Ki | 6.40 | IUPHAR |
ID | Source |
---|---|
4019646 | VUID |
N0000147739 | NUI |
D00702 | KEGG_DRUG |
33386-08-2 | SECONDARY_CAS_RN |
4018813 | VANDF |
4019646 | VANDF |
C0006462 | UMLSCUI |
CHEBI:3223 | CHEBI |
CHEMBL49 | ChEMBL_ID |
CHEMBL1200399 | ChEMBL_ID |
DB00490 | DRUGBANK_ID |
D002065 | MESH_DESCRIPTOR_UI |
3456 | INN_ID |
2477 | PUBCHEM_CID |
36 | IUPHAR_LIGAND_ID |
TK65WKS8HL | UNII |
1827 | RXNORM |
37673 | MMSL |
4308 | MMSL |
d00182 | MMSL |
001468 | NDDF |
004586 | NDDF |
387523009 | SNOMEDCT_US |
419484002 | SNOMEDCT_US |
91452003 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-0053 | TABLET | 5 mg | ORAL | ANDA | 29 sections |
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-0054 | TABLET | 10 mg | ORAL | ANDA | 29 sections |
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1003 | TABLET | 15 mg | ORAL | ANDA | 29 sections |
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5200 | TABLET | 30 mg | ORAL | ANDA | 29 sections |
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-1140 | TABLET | 5 mg | ORAL | ANDA | 27 sections |
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-1145 | TABLET | 7.50 mg | ORAL | ANDA | 27 sections |
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-1150 | TABLET | 10 mg | ORAL | ANDA | 27 sections |
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-1165 | TABLET | 15 mg | ORAL | ANDA | 27 sections |
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-1175 | TABLET | 30 mg | ORAL | ANDA | 27 sections |
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-4575 | TABLET | 10 mg | ORAL | ANDA | 29 sections |
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-4595 | TABLET | 5 mg | ORAL | ANDA | 29 sections |
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-4596 | TABLET | 15 mg | ORAL | ANDA | 29 sections |
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-7633 | TABLET | 5 mg | ORAL | ANDA | 30 sections |
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-7634 | TABLET | 10 mg | ORAL | ANDA | 30 sections |
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-7635 | TABLET | 15 mg | ORAL | ANDA | 30 sections |
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-7689 | TABLET | 15 mg | ORAL | ANDA | 30 sections |
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-7714 | TABLET | 5 mg | ORAL | ANDA | 30 sections |
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-7718 | TABLET | 10 mg | ORAL | ANDA | 30 sections |
Buspirone hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6899 | TABLET | 15 mg | ORAL | ANDA | 22 sections |
Buspirone HCl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-176 | TABLET | 10 mg | ORAL | ANDA | 27 sections |
BUSPIRONE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-375 | TABLET | 30 mg | ORAL | ANDA | 27 sections |
BUSPIRONE HCl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-579 | TABLET | 15 mg | ORAL | ANDA | 27 sections |
BUSPIRONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-600 | TABLET | 10 mg | ORAL | ANDA | 13 sections |
BUSPIRONE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-727 | TABLET | 7.50 mg | ORAL | ANDA | 26 sections |
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-200 | TABLET | 5 mg | ORAL | ANDA | 29 sections |
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-201 | TABLET | 7.50 mg | ORAL | ANDA | 29 sections |
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-202 | TABLET | 10 mg | ORAL | ANDA | 29 sections |
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-203 | TABLET | 15 mg | ORAL | ANDA | 29 sections |
Buspirone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-289 | TABLET | 30 mg | ORAL | ANDA | 29 sections |
Buspirone HCl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-172 | TABLET | 15 mg | ORAL | ANDA | 27 sections |